Fitzgerald Kevin Joseph 4

What Happened

• Kevin J. Fitzgerald, CSO & EVP, Head of Research at Alnylam Pharmaceuticals, sold a total of 1,291 ALNY shares in open-market transactions on March 4–5, 2026, generating approximately $417,685 in proceeds. Individual lots ranged from 28 to 233 shares at prices between about $319 and $326 per share.
• These were sales (routine disposition), not purchases; several sales appear to be automatic tax-withholding sell-to-cover transactions tied to vesting restricted stock units, and at least one sale was executed under a Rule 10b5-1 trading plan.

Key Details

• Transaction dates: 2026-03-04 and 2026-03-05. Report filed 2026-03-06 (filed within the typical 2-business-day Form 4 window).
• Shares sold: 1,291 total; proceeds ≈ $417,685; weighted-average price ≈ $323.6/share (approx).
• Notable footnotes: filing indicates mandatory sell-to-cover for RSU tax withholding and at least one transaction pursuant to a Rule 10b5-1 plan adopted Aug 14, 2025. Several reported prices represent weighted averages across narrow price ranges (see footnotes F2–F14).
• Shares owned after the transactions: not disclosed in the provided excerpt of the filing.
• Filing timeliness: appears timely (filed Mar 6 for trades on Mar 4–5).

Context

• Sales used to satisfy tax withholding on vested awards (sell-to-cover) are routine and do not necessarily indicate a change in the insider’s view of the company. A 10b5-1 plan means at least some trades were pre-scheduled and not ad hoc.
• For retail investors, purchases generally carry more interpretive weight than routine sales; these transactions appear to be standard compensation/tax-related and plan-driven dispositions rather than opportunistic buys or large strategic sells.